Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03SGR
|
||||
| Former ID |
DAP001095
|
||||
| Drug Name |
Efalizumab
|
||||
| Synonyms |
Raptiva; Raptiva (TN); Efalizumab (USAN/INN)
|
||||
| Drug Type |
Antibody
|
||||
| Therapeutic Class |
Immunomodulatory Agents
|
||||
| Company |
Roche
|
||||
| CAS Number |
CAS 214745-43-4
|
||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
L04AA21
|
||||
| Target and Pathway | |||||
| Target(s) | Lymphocyte function-associated antigen 1 | Target Info | [537313] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| Cell adhesion molecules (CAMs) | |||||
| Natural killer cell mediated cytotoxicity | |||||
| Leukocyte transendothelial migration | |||||
| Regulation of actin cytoskeleton | |||||
| Malaria | |||||
| Staphylococcus aureus infection | |||||
| HTLV-I infection | |||||
| Epstein-Barr virus infection | |||||
| Rheumatoid arthritis | |||||
| Viral myocarditis | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| Pathway Interaction Database | Integrin family cell surface interactions | ||||
| Beta2 integrin cell surface interactions | |||||
| CXCR3-mediated signaling events | |||||
| References | |||||
| Ref 537129 | New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. | ||||
| Ref 541714 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6593). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.